Gjoni Tina, Urwyler Stephan
Novartis Institutes for BioMedical Research, Neuroscience, Basel, Switzerland.
Eur J Pharmacol. 2009 Jan 28;603(1-3):37-41. doi: 10.1016/j.ejphar.2008.12.014. Epub 2008 Dec 16.
It has been estimated that only 15% of the compounds classified as silent G protein-coupled receptor antagonists are indeed devoid of either positive or negative intrinsic efficacy. Considering that 40% of all drugs on the market target G protein-coupled receptors mainly as orthosteric ligands, elucidating their intrinsic properties is becoming increasingly important. While agonism can be demonstrated using appropriately sensitive experimental setups, the detection of inverse agonism can be limited by a low degree of constitutive activity in many assay systems. In this study, changes in ligand behavior upon a lasting pretreatment with gamma-aminobutyric acid (GABA), that induced receptor desensitization, were observed, measuring the second messenger cyclic AMP (cAMP) in a GABA(B) receptor-expressing recombinant cell line. The GABA(B) receptor partial agonist 2-OH-saclofen lost its ability to inhibit 7beta-forskolin-induced cAMP production upon GABA-pretreatment. The "silent" receptor antagonists CGP62349, CGP52432, CGP56999 and SCH50911, on the other hand, stimulated 7beta-forskolin-induced cAMP production under these conditions. The inverse agonism of CGP56999 was inhibited by the efficacy-deficient 2-OH-saclofen, proving it was truly mediated through the orthosteric site of the GABA(B) receptor. Finally, the positive allosteric modulator GS39783, which previously only marginally inhibited cAMP production, suppressed it by 60% both alone and in the presence of the competitive receptor antagonist 2-OH-saclofen, thus GS39783 became an allosteric receptor agonist at desensitized GABA(B) receptors. These changes likely reflect adaptations in the mechanisms of GABA(B) receptor function following desensitization and may be important in the elucidation of intrinsic ligand efficacies as well as for the consequences of continuous drug treatment.
据估计,在被归类为沉默型G蛋白偶联受体拮抗剂的化合物中,只有15%确实没有正性或负性内在活性。鉴于市场上40%的药物主要作为正位配体作用于G蛋白偶联受体,阐明它们的内在特性变得越来越重要。虽然可以使用适当灵敏的实验装置来证明激动作用,但在许多检测系统中,反向激动作用的检测可能会受到组成性活性程度较低的限制。在本研究中,观察了用γ-氨基丁酸(GABA)进行持久预处理诱导受体脱敏后配体行为的变化,该预处理在表达GABA(B)受体的重组细胞系中测量第二信使环磷酸腺苷(cAMP)。GABA(B)受体部分激动剂2-羟基-舒氯芬在GABA预处理后失去了抑制7β-佛司可林诱导的cAMP产生的能力。另一方面,“沉默”受体拮抗剂CGP62349、CGP52432、CGP56999和SCH50911在这些条件下刺激了7β-佛司可林诱导的cAMP产生。CGP56999的反向激动作用被缺乏效力的2-羟基-舒氯芬抑制,证明其确实是通过GABA(B)受体的正位位点介导的。最后,先前仅轻微抑制cAMP产生的正变构调节剂GS39783,单独使用以及在竞争性受体拮抗剂2-羟基-舒氯芬存在的情况下均将其抑制了60%,因此GS39783在脱敏的GABA(B)受体处成为变构受体激动剂。这些变化可能反映了脱敏后GABA(B)受体功能机制的适应性变化,并且在阐明内在配体效力以及连续药物治疗的后果方面可能很重要。